Maurizia R. Brunetto is Director of the Integrated Care Department of Medical Specialties and of the Liver Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses of Pisa University Hospital.  Her research activity has been focused on the study of the pathogenetic implications of hepatitis virus infection, on the analysis of factors influencing the progression of chronic hepatitis to cirrhosis and hepatocellular carcinoma and on the treatment optimization. She did seminal work in the clinic-pathologic characterization of the HBeAg negative chronic hepatitis B with the identification of Pre-core mutant and demonstrated  the clinical usefulness of HBsAg serum levels measurement in the monitoring of antiviral      therapy and identification of HBeAg negative infection with the definition of the clinical cut-off, currently suggested by the international guidelines.

Lindsey Hiebert is the Associate Director of the Coalition for Global Hepatitis Elimination. The Coalition is based at the Task Force for Global Health, an international NGO in Atlanta, United States. At the Coalition, Lindsey supports initiatives related to technical assistance, operational research, advocacy, and policy to advance hepatitis B and C elimination globally.

Dr Jess Dyson is a consultant hepatologist at the Freeman Hospital in Newcastle with a combined role as an NHS hepatologist with a major interest in clinical research based at Newcastle University. She leads the clinical service in Newcastle for patients with autoimmune liver disease including running the regional network for delivery of 2nd-line therapies in high risk primary biliary cholangitis. She is principal investigator for the UK national study for patients with autoimmune hepatitis that focuses on improving therapy for patients (UK-AIH) and a co-author on the national guidelines for primary biliary cholangitis, primary sclerosing cholangitis and autoimmune hepatitis. She completed her PhD in 2019 investigating potential environmental risk factors related to autoimmune liver disease.

Robert Mitchell-Thain is Chief Executive Officer at the PBC Foundation and Chair of Paediatric and Rare Liver Diseases Council at the Global Liver Institute. Mitchell-Thain is a fierce patient advocate with over 20 years of international experience. A NAFLD patient himself, his main focus has been cholestatic liver disease. A member of numerous collaborative committees, lead and co-author on several patient-centric abstracts, co-author and reviewer of clinical guidelines and journal articles, he is known for challenging dogma and for a progressive approach to finding solutions in a patient-centred way, pursuing the best for all stakeholders within the community.

Jeffrey V. Lazarus (Ph.D., MIH, MA) is a Member of the EASL Policy and Public Health Committee. He holds positions as an associate research professor at the Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, where he leads the health systems research team, as Associate Professor at the Faculty of Medicine, University of Barcelona, Spain and as a senior scholar at the CUNY Graduate School of Public Health and Policy in New York City. His decade-long career as health systems, HIV, and viral hepatitis expert at WHO Europe was followed by three years (2009-2012) as a senior specialist at the Global Fund to Fight AIDS, Tuberculosis, and Malaria, three years as director of Health Systems Global (2012-15) then board chair of the foundation AFEW International (2015-18). Prof Lazarus is now Vice-Chairman of the board of the EASL International Liver Foundation, where he developed the micro-elimination approach to HCV elimination. He is also a member of the INHSU international education committee and co-chair of the HIV Outcomes Beyond Viral Suppression coalition. He is the author of more than 300 publications and his current scientific work includes leading the Hep C Free Baleares, HBV COMSAVA, and Copenhagen T'n'T studies, and the Global COVID-19 consensus statement on ending the pandemic. He is a core member of The Lancet GastroHep Commission on Viral Hepatitis, a co-author of the Lancet COVID-19 commission and a commissioner of the EASL-Lancet European Liver Commission and The Lancet-IAPAC HIV Commission. At AME/VE he is chair of the NAFLD models of care workshop, on the organizing committee of COLDA, and on the scientific committee of IVHEM.

Prof. Maja Thiele works to reduce morbidity and mortality from alcohol-related liver disease, for the benefit of an otherwise stigmatized patient group. Her research centers on the development and validation of diagnostic and prognostic biomarkers, with a particular focus on early disease detection, cost-effective referral pathways and omics technologies. Elastography expert contributor to EASL Clinical Practice Guidance, the BAVENO VII consensus statement, AASLD clinical guidance, WFUMB guideline, and The Lancet Commission on liver disease in primary care. Partner in the European research consortia GALAXY, LiverScreen, LIVERAIM, MicrobPredict and SALVE.

Josep M. Llovet, MD, PhD is Professor of Medicine – Hepatic Oncology at University of Barcelona, Group leader and Professor of Research-ICREA in the Liver Unit, IDIBAPS-Hospital Clinic and Director of the Liver Cancer Program and Professor of Medicine at the Icahn School of Medicine at Mount Sinai, NY. He has devoted his career to the pathogenesis and treatment of liver cancer, publishing ~ 350 articles (~ 136,049 citations, h index: 134) and leading ~100 projects. He has been nominated as global Top-1% cited researcher (2014 to 2022) and nominated Editor in Chief of JHEP Reports (2024-29).

Richard Price is Head of Policy at European Cancer Organisation (ECO). He is a public policy professional with extensive experience in the healthcare and pharmaceutical sectors working as a policy manager in EU Affairs at ECO, policy and advocacy officer at the European Association of Hospital Pharmacists, and as policy advisor to the Pharmaceutical Society of Northern Ireland.

Nick Sheron is an academic clinical hepatologist at University of Southampton and runs the liver unit at Southampton General Hospital. He is also actively involved in a clinically based programme of research in various aspects of alcohol-related problems. Together with Ian Gilmore, President of the Royal College of Physicians, he co-founded the Alcohol Health Alliance UK, an umbrella body bring together 27 different organisations including Royal Colleges, NGOs and charities with the aim of lobbying for evidence-based policies to reduce alcohol-related harm in the UK. He is also a founder member of the European Union Alcohol Forum, a member of the European Union Alcohol Marketing Taskforce and two bodies of which have been set up by the European Commission in order to take forward the EU Alcohol Strategy.

Florence Berteletti has over 20 years of international policy and advocacy experience in diverse fields including fiscal policies for health, tobacco control, alcohol related harm and culture policy. Florence Berteletti was appointed Secretary General of Eurocare in August 2021. Between 2018 and August 2021, Florence was Advocacy Director at the World Heart Federation where she was responsible for leading WHF’s global policy and advocacy and led dossiers related to Front of Pack Labelling, Fiscal Policies for Health, Rheumatic Heart Diseases and Air pollution, to name just a few. Before WHF, Florence was Director of the Smoke Free Partnership (SFP), an alliance of 52 civil society organisations dedicated to the implementation of the WH Framework Convention on Tobacco Control (FCTC).